BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 34699621)

  • 1. Three LHPP gene-targeting co-expressed microRNAs (microRNA-765, microRNA-21, and microRNA-144) promote proliferation, epithelial-mesenchymal transition, invasion, and are independent prognostic biomarkers in renal cell carcinomas patients.
    Meng K; Li Z; Cui X
    J Clin Lab Anal; 2021 Dec; 35(12):e24077. PubMed ID: 34699621
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MicroRNA-200b is downregulated and suppresses metastasis by targeting LAMA4 in renal cell carcinoma.
    Li Y; Guan B; Liu J; Zhang Z; He S; Zhan Y; Su B; Han H; Zhang X; Wang B; Li X; Zhou L; Zhao W
    EBioMedicine; 2019 Jun; 44():439-451. PubMed ID: 31130475
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LHPP Inhibits the Proliferation and Metastasis of Renal Cell Carcinoma.
    Zhang X; Kang H; Xiao J; Shi B; Li X; Chen G
    Biomed Res Int; 2020; 2020():7020924. PubMed ID: 33426063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. miR-1293 Suppresses Tumor Malignancy by Targeting Hydrocyanic Oxidase 2: Therapeutic Potential of a miR-1293/Hydrocyanic Oxidase 2 Axis in Renal Cell Carcinoma.
    Liu XL; Pan WG; Li KL; Mao YJ; Liu SD; Zhang RM
    Cancer Biother Radiopharm; 2020 Jun; 35(5):377-386. PubMed ID: 31971830
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Downregulation of LHPP Expression Associated with AFP Acts as a Good Prognostic Factor in Human Hepatocellular Carcinoma.
    Chao X; Zhang W; Wu J; Feng X; Shi H; Zhao L; Shen H; Jiang C
    Biomed Res Int; 2021; 2021():1971048. PubMed ID: 34485511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CRNDE mediates the viability and epithelial-mesenchymal transition of renal cell carcinoma via miR-136-5p.
    Zhang Y; Lan X; Wang Y; Liu C; Cui T
    J Recept Signal Transduct Res; 2021 Jun; 41(3):234-244. PubMed ID: 32808846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MiRNA-206 inhibits proliferation of renal clear cell carcinoma by targeting ZEB2.
    Chen XF; Guo JF; Xu JF; Yin SH; Cao WL
    Eur Rev Med Pharmacol Sci; 2019 Sep; 23(18):7826-7834. PubMed ID: 31599407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CEP55 promotes epithelial-mesenchymal transition in renal cell carcinoma through PI3K/AKT/mTOR pathway.
    Chen H; Zhu D; Zheng Z; Cai Y; Chen Z; Xie W
    Clin Transl Oncol; 2019 Jul; 21(7):939-949. PubMed ID: 30607788
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pseudogene HSPB1P1 contributes to renal cell carcinoma proliferation and metastasis by targeting miR-296-5p to regulate HMGA1 expression.
    Chen Z; Wang Z; Chen Z; Fu F; Huang X; Huang Z
    Cell Biol Int; 2021 Dec; 45(12):2479-2489. PubMed ID: 34431162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An increased level of MiR-222-3p is associated with TMP2 suppression, ERK activation and is associated with metastasis and a poor prognosis in renal clear cell carcinoma.
    Lyu J; Zhu Y; Zhang Q
    Cancer Biomark; 2020; 28(2):141-149. PubMed ID: 32116235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MicroRNAs in the pathogenesis of renal cell carcinoma and their diagnostic and prognostic utility as cancer biomarkers.
    Fedorko M; Pacik D; Wasserbauer R; Juracek J; Varga G; Ghazal M; Nussir MI
    Int J Biol Markers; 2016 Feb; 31(1):e26-37. PubMed ID: 26481440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Downregulation of microRNA-15a suppresses the proliferation and invasion of renal cell carcinoma via direct targeting of eIF4E.
    Li G; Chong T; Xiang X; Yang J; Li H
    Oncol Rep; 2017 Oct; 38(4):1995-2002. PubMed ID: 28849086
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Liao L; Duan D; Liu Y; Chen L
    Cell Cycle; 2020 Jul; 19(14):1846-1854. PubMed ID: 32578511
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor suppressor LHPP suppresses cell proliferation and epithelial-mesenchymal transition in hepatocellular carcinoma cell lines.
    Ma L; Sun H; Xu X; Chen Y; Zhang L; Li S; Tang L
    J Physiol Biochem; 2022 Nov; 78(4):807-817. PubMed ID: 35796893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. microRNA‑572 functions as an oncogene and a potential biomarker for renal cell carcinoma prognosis.
    Pan X; Li Z; Zhao L; Quan J; Zhou L; Xu J; Xu W; Guan X; Li H; Yang S; Gui Y; Lai Y
    Oncol Rep; 2018 Nov; 40(5):3092-3101. PubMed ID: 30132566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Significance of Circular RNA DDX17 in Prostate Cancer.
    Lin Q; Cai J; Wang QQ
    Biomed Res Int; 2020; 2020():1878431. PubMed ID: 32904557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MiR-429 is linked to metastasis and poor prognosis in renal cell carcinoma by affecting epithelial-mesenchymal transition.
    Machackova T; Mlcochova H; Stanik M; Dolezel J; Fedorko M; Pacik D; Poprach A; Svoboda M; Slaby O
    Tumour Biol; 2016 Nov; 37(11):14653-14658. PubMed ID: 27619681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LHPP suppresses tumorigenesis of intrahepatic cholangiocarcinoma by inhibiting the TGFβ/smad signaling pathway.
    Wang D; Ning Z; Zhu Z; Zhang C; Wang P; Meng Z
    Int J Biochem Cell Biol; 2021 Mar; 132():105845. PubMed ID: 33401010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MicroRNA-218 inhibits cell migration and invasion in renal cell carcinoma through targeting caveolin-2 involved in focal adhesion pathway.
    Yamasaki T; Seki N; Yoshino H; Itesako T; Hidaka H; Yamada Y; Tatarano S; Yonezawa T; Kinoshita T; Nakagawa M; Enokida H
    J Urol; 2013 Sep; 190(3):1059-68. PubMed ID: 23454155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. miR-134 functions as a tumor suppressor in cell proliferation and epithelial-to-mesenchymal Transition by targeting KRAS in renal cell carcinoma cells.
    Liu Y; Zhang M; Qian J; Bao M; Meng X; Zhang S; Zhang L; Zhao R; Li S; Cao Q; Li P; Ju X; Lu Q; Li J; Shao P; Qin C; Yin C
    DNA Cell Biol; 2015 Jun; 34(6):429-36. PubMed ID: 25811077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.